Teprotumumab for Thyroid Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Real-World Studies.
TOPIC Teprotumumab is the first FDA-approved biologic for moderate-to-severe thyroid eye disease (TED). Although efficacy has been established in randomized controlled trials (RCTs), real-world studies (RWS) have reported different efficacy and safety patterns, supporting an updated synthesis. CLINICAL RELEVANCE A co...